Application of Bifidobacterium animalis subsp. lactis in neuroprotection

By using the animal Lactobacillus subspecies NJ241 of Bifidobacterium Bifidobacterium, the treatment of neurodegenerative diseases was directly solved, and the treatment effect in the prior art was not direct, neuroprotection and inflammation regulation were achieved, and Parkinson's disease mice were significantly improved. sports injury and intestinal ecology.

CN117018040BActive Publication Date: 2024-11-19THANKCOME BIOLOGICAL SCI & TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311047234.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-08-18
Publication Date
2024-11-19
Estimated Expiration
2043-08-18

AI Technical Summary

Technical Problem

The existing animal Bifidobacterium used in the treatment of neurodegenerative diseases is mostly auxiliary, and cannot directly play a therapeutic effect, and it is difficult to achieve the expected effect when used alone.

Method used

Provides a subsp. Bifidobacterium animalis subsp. Lactis, deposit number CGMCC No. 20816, called NJ241), which is directly used for neuroprotection through oral form, alleviating neuroinflammation and inhibiting substantia nigra Cell activation, activates PGC-1α, protects dopaminergic neurons, and regulates intestinal microecology.

Benefits of technology

NJ241 can improve motor injury in Parkinson's disease mice, increase the number of dopaminergic neurons, inhibit the activation of substantia nigra, improve the blood-brain barrier, reduce the abundance of inflammatory bacteria, increase the abundance of beneficial bacteria, and promote GLP-1 and PGC. The expression of -1α significantly exerts a neuroprotective effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117018040B_ABST
    Figure CN117018040B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of microbial application technology, and in particular to the application of animal Bifidobacterium lactis subspecies in neuroprotection. The animal Bifidobacterium lactis subspecies NJ241 involved in the present invention is a public strain with a preservation number of CGMCCNo.20816. The present invention verifies through mouse experiments that NJ241 can improve motor impairment in PD mice, increase the number and protein level of dopaminergic neurons; inhibit the activation of substantia nigra glial cells, and improve the blood-brain barrier. NJ241 improves the intestinal dysbiosis caused by MPTP, reduces the abundance of inflammatory bacteria, and increases the abundance of beneficial bacteria. NJ241 also increases the expression level of GLP‑1 in the colon and promotes the expression of GLP‑1R / PGC‑1α in the substantia nigra. According to the experimental results, NJ241 can play a neuroprotective role, and then play a role in preventing or treating neurodegenerative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of microorganisms, and in particular relates to application of animal Bifidobacterium lactis subspecies in neuroprotection. Background Art

[0002] Parkinson's disease (PD) is a neurodegenerative disease whose main pathological features are the degeneration and death of DA neurons in the SNc and the aggregation of LBs mainly composed of α-synuclein, which destroys the nigrostriatal system and manifests as motor symptoms such as muscle rigidity, resting tremor, bradykinesia, and gait disorder.

[0003] However, current studies have found that PD patients often show non-motor symptoms before the onset of motor symptoms, such as gastrointestinal dysfunction, olfactory abnormalities, depression, sleep disorders, etc. The cause of Parkinson's disease has not been confirmed so far. It is related to genetics, environmental factors, oxidative stress, neuroinflammation, etc. Braak et al. proposed that intestinal α-synuclein deposition will retrogradely transfer to the central nervous system, and studies have confirmed that different α-synuclein proteins can spread from the intestine to the brain. Recent population-based studies have shown that inflammatory bowel disease may increase the risk of Parkinson's disease. In addition, the Parkinson's disease pathogenic gene LRRK2 was found to be associated with Crohn's disease. There is increasing evidence that Parkinson's disease is closely related to the intestine.

[0004] The gut microbiota (GM) has been called the "second brain" and has 10 times more cells than human cells. In addition, the total genome of the GM contains about 3 million genes, which is 150 times that of the human genome. Probiotics are defined as live microorganisms that will help promote the health of the host in sufficient quantities. Studies have shown that probiotics have multiple benefits for the host's body, such as anti-aging, anti-cancer, and cholesterol-lowering. Of particular interest is that some probiotics have been shown to be involved in the regulation of neurological diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

[0005] Bifidobacterium is one of the most important probiotics in the intestine. It maintains a relatively stable level throughout the life of an adult and gradually decreases in the human intestine during aging. Studies have shown that bifidobacteria can promote the secretion of short-chain fatty acids (SCFA). SCFA plays a positive role in PD, such as promoting GLP-1 secretion, improving behavioral damage caused by MPTP in PD mice, DA neuron death, and reduced tight junction protein expression. GLP-1 is secreted by colonic L cells and can bind to its receptor GLP-1R to exert its effects. GIP-1R can be detected in the substantia nigra. Activation of GLP-1R can improve behavioral damage in PD mice, inhibit neuroinflammation, and protect dopaminergic neurons. The MG1363-pMG36e-GLP-1 engineered strain significantly reduced intestinal pathogenic bacteria Enterobacteriaceae, significantly increased probiotics Lactobacillus and Akkermansia, improved MPTP-induced motor damage, increased tyrosine hydroxylase (TH)-positive neurons, and inhibited the activation of microglia and astrocytes.

[0006] PGC-1α is an important transcriptional coactivator that participates in regulating cellular metabolism and energy homeostasis. PGC-1α is mainly expressed in tissues such as the liver, muscle, heart, and brain. PGC-1α can interact with a variety of transcription factors and participate in regulating inflammatory responses in the body. Mutations in its genes and reduced expression levels are the pathogenic mechanisms of many inflammatory-related diseases. The GLP-1R agonist liraglutide can inhibit substantia nigra inflammation through the GLP-1R / PGC-1α pathway, regulate the mitochondrial mass of the substantia nigra, and exert a neuroprotective effect on PD mice.

[0007] When the animal bifidobacteria disclosed in the prior art are used for the treatment of neurodegenerative diseases, they mostly play an auxiliary therapeutic role by adjusting emotions, improving sleep, and alleviating constipation, rather than directly acting on nerves. For example, the Chinese patent with application number CN202010449945.7 discloses Bifidobacterium lactis Probio-M8 and its application for relieving and treating Parkinson's disease. Through a comprehensive evaluation of clinical symptom surveys, constipation situation surveys, treatment satisfaction and the possibility of continuous medication, it is finally shown that taking Bifidobacterium lactis Probio-M8 while taking Parkinson's disease treatment drugs Madopar and Pramipexole can significantly reduce patients' anxiety and depression, improve patients' sleep quality, reduce the degree of constipation, reduce stool hardness, defecation effort and incomplete defecation, improve stool characteristics, increase the number of spontaneous bowel movements and complete bowel movements per week, and ultimately improve patients' treatment satisfaction and the possibility of continuous medication, thereby achieving the effect of relieving and treating Parkinson's disease, anxiety and constipation. Although it is used for Parkinson's disease, it does not actually play a direct role in the treatment. In other words, it cannot be separated from the combination of existing drugs. The Bifidobacterium lactis JYBR-190 disclosed in the Chinese patent application number CN202210439953.2 needs to be combined with multiple bacteria and the fermentation product obtained by substrate fermentation for application. The method is complicated and it cannot achieve the corresponding therapeutic effect when used alone. Summary of the invention

[0008] In order to solve the above problems, the present invention provides an animal Bifidobacterium lactis subspecies that can directly treat neurodegenerative diseases, and verifies its mechanism of action, thereby providing a new drug selection scheme for the treatment of neurodegenerative diseases, which is suitable for clinical use.

[0009] In one aspect, the present invention provides the use of Bifidobacterium animalis subsp. Lactis in the preparation of a neuroprotective health product or medicine.

[0010] The animal Bifidobacterium lactis subspecies is deposited with CGMCC No. 20816, also known as animal Bifidobacterium lactis subspecies NJ241, or NJ241 for short.

[0011] The animal Bifidobacterium lactis subspecies was deposited with the China National Microbiological Culture Collection Administration on September 24, 2020, and was first disclosed in the invention patent with publication number CN115466696A.

[0012] The neuroprotection includes, but is not limited to, alleviating neuroinflammation, protecting dopaminergic neurons, and activating PGC-1α.

[0013] Specifically, the reduction of neuroinflammation includes, but is not limited to: improving the blood-brain barrier, inhibiting the activation of substantia nigra cells, or balancing inflammatory bacteria / probiotics and regulating intestinal microecology.

[0014] More specifically, the inhibition of nigral glial cell activation includes reducing the expression levels of inflammatory mediators and cytokines in nigral glial cells.

[0015] Furthermore, the substantia nigra cells include astrocytes or microglia.

[0016] More specifically, the improvement of the ecology of intestinal inflammatory bacteria and beneficial bacteria includes reducing the abundance of inflammatory bacteria and increasing the abundance of beneficial bacteria.

[0017] Specifically, the protection of dopaminergic neurons includes increasing the number and protein level of dopaminergic neurons.

[0018] Specifically, the activation of PGC-1α includes promoting the expression of colon GLP-1 and acting on GLP-1R in the substantia nigra to activate PGC-1α.

[0019] The medicine or health product is preferably in oral form.

[0020] Preferably, the drug includes no less than 10 8 CFU / g or 10 8 CFU / mL of the Bifidobacterium animalis subsp. lactis

[0021] On the other hand, the present invention provides the use of the aforementioned Bifidobacterium animalis subsp. lactis with the deposit number of CGMCC No. 20816 in the preparation of a medicament for preventing or treating a neurodegenerative disease.

[0022] The neurodegenerative diseases include but are not limited to Parkinson's disease.

[0023] The drug can prevent or treat neurodegenerative diseases by exerting a neuroprotective effect.

[0024] The drug is preferably an oral drug.

[0025] Preferably, the oral medication includes no less than 10 8 CFU / g or 10 8 CFU / mL of the Bifidobacterium animalis subsp. lactis.

[0026] Beneficial effects of the present invention:

[0027] The present invention provides a new application of Bifidobacterium lactis subspecies animalis with a preservation number of CGMCC No. 20816, and verifies that NJ241 can improve motor impairment in PD mice, increase the number and protein level of dopaminergic neurons; inhibit the activation of substantia nigra glial cells, and improve the blood-brain barrier. NJ241 improves intestinal dysbiosis caused by MPTP, reduces the abundance of inflammatory bacteria, and increases the abundance of beneficial bacteria. NJ241 also increases the expression level of GLP-1 in the colon and promotes the expression of GLP-1R / PGC-1α in the substantia nigra. According to the experimental results, NJ241 can play a neuroprotective role, thereby playing a role in preventing or treating neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The experimental steps of Example 1 and the results of the effects of NJ241 on body weight, gastrointestinal motility and behavior. Wherein: (A) Experimental process; (B) represents the change in body weight; (C) represents the small intestine transit distance; (D), (E), (F), (G) show the behavioral test results after injection of MPTP (number of activities, number of independent standing times, rotation latency and hanging score). a means P<0.05 compared with the control group, aa means P<0.01 compared with the control group; b group means P<0.05 compared with the NJ241 group, bb group means P<0.01 compared with the NJ241 group; c means P<0.05 compared with the MPTP group, cc group means P<0.01 compared with the MPTP group.

[0029] Figure 2 The results of NJ241 increasing the DA level in MPTP-treated mice. Among them: (A) Immunofluorescence staining results. (B) Quantitative detection of the number of TH-positive cells in mouse SN (n=6). (C) Western blot bands of each group (n=3). (D) Detection of TH protein levels in each group. a indicates P<0.05 compared with the control group, aa indicates P<0.01; bb indicates P<0.01 compared with the NJ241 group; c indicates P<0.05, cc indicates P<0.01 compared with the MPTP group. Scale bar = 100μm. SNc is substantia nigra pars compacta; SNr is substantia nigra pars reticularis.

[0030] Figure 3The inhibitory effect of NJ241 on the activation of GFAP and Iba-1 in the substantia nigra, including: (A) Immunofluorescence staining of microglia in SN, (B) Immunofluorescence staining of astrocytes in SN, scale bar = 100 μm. (C) Quantification of Iba-1 positive cells; (D) Average optical density quantification of GFAP; (E) Protein bands of GFAP; (F) Statistical analysis of GFAP protein bands. (G), (I), (K) Protein bands of IL-1β, IL-6 and NF-κB. (H), (J), (L) Statistical analysis of IL-1β, IL-6, and NF-κB protein levels. Immunofluorescence n = 6, immunoblotting n = 3. a means P < 0.05 compared with the control group, aa means P < 0.01; b means P < 0.05 compared with the NJ241 group, bb means P < 0.01; c means P < 0.05 relative to the MPTP group, cc means P < 0.01. SNc is the substantia nigra pars compacta; SNr is the substantia nigra pars reticularis.

[0031] Figure 4 NJ241 alleviates the damage of MPTP to SN tight junctions, including: (A) ZO-1 protein band in SN. (B) Human tight junction protein band in SN. (C) Relative quantification of ZO-1 in SN. (D) Relative quantification of human tight junction protein in SN. n=3, compared with the control group, aa means P<0.01; compared with the NJ241 group, b means P<0.05, bb means P<0.01; compared with the MPTP group, cc means P<0.01.

[0032] Figure 5 The results of NJ241 intervention to improve the intestinal flora structure and diversity of MPTP mice, including: (A) α-diversity Chao1 index analysis; (B) α-diversity Simpson index analysis; showing the diversity of intestinal microbiota in different groups of mice; (C) PCoA showing the similarity of intestinal microbiota in different groups of mice; (D) species annotation showing the relative abundance of intestinal microbiota in different groups of mice at the phylum level; (E) species annotation showing the relative abundance of intestinal microbiota in different groups of mice at the genus level; (F) Changes in the main intestinal microbiota in different groups of mice at the genus level. a indicates P < 0.05 compared with the control group; b indicates P < 0.05 compared with the NJ241 group.

[0033] Figure 6Effects of NJ241 on the expression of GLP-1 in colon, GLP-1R and PGC-1α in SN, including: (A) Protein network analysis of common differentially expressed genes in Parkinson's disease and diabetes. (B) GLP-1 protein bands in colon (C) GLP-1 expression level in colon, (D) GLP-1 concentration in serum, (E) GLP-1R protein bands in SN, (F) GLP-1R protein level in SN. (G) GLP-1R positive cells in SN, (H) Number of GLP-1R positive cells in SN. (I) PGC-1α protein bands in SN. (J) Expression level of PGC-1α protein in SN. a means P<0.05 compared with the control group; aa means P<0.01 compared with the control group; b means P<0.05 compared with the NJ241 group; bb means P<0.01 compared with the NJ241 group; c means P<0.05 compared with the MPTP group; cc means P<0.01 compared with the MPTP group.

[0034] Figure 7 The mechanism by which NJ241 exerts neuroprotective effects in PD mice. DETAILED DESCRIPTION

[0035] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0036] In the present invention, "SN" refers to substantia nigra, which is the abbreviation of substantia nigra, and is a basal ganglia structure located in the midbrain.

[0037] In the present invention, "TH" refers to tyrosine hydroxylase.

[0038] In the present invention, "ZO-1" is a protein located under the cell membrane, which forms a structure of intercellular connection together with other tight junction proteins.

[0039] In the following examples, MPTP was purchased from MedChemExpress (MCE) as an example.

[0040] In the following examples, NJ241 refers to Bifidobacterium animalis subsp. lactis NJ241, whose deposit number is CGMCCNO.20816 and is from Shan En Kang Biotechnology (Suzhou) Co., Ltd.

[0041] Rabbit anti-TH polyclonal antibody, rabbit anti-GLP-1R polyclonal antibody, rabbit anti-GFAP polyclonal antibody, mouse anti-GAPDH polyclonal antibody were purchased from Wuhan Sanying Biotechnology Co., Ltd. (Cat. No. 25859-1-AP, 26196-1-AP, 16825-1-AP, 60004-1-Ig, respectively). Rabbit anti-Iba-1 monoclonal antibody, rabbit anti-PGC-1α monoclonal antibody, rabbit anti-GLP-1R monoclonal antibody were all purchased from Abcam (Cat. No. ab178847, ab188102, ab218532, respectively). Rabbit anti-ZO-1 polyclonal antibody was purchased from Servicebio (GB111402, Wuhan), and rabbit anti-human tight junction protein polyclonal antibody was purchased from Wanlei Biological (WL01996, Shenyang). Rabbit anti-GLP-1 polyclonal antibody, goat anti-rabbit IgG labeled with Alexa fluor 594, goat anti-mouse IgG labeled with horseradish peroxidase, and goat anti-rabbit IgG labeled with horseradish peroxidase were purchased from Abways (catalog numbers CY6623, AB0151, AB0102, and AB0101, respectively).

[0042] Example 1

[0043] The experimental animals were male C57BL / 6 mice weighing 20±2g. The animals were placed in a 12h / 12h light-dark cycle environment at a constant temperature of 25°C. After acclimation, behavioral training was performed for 2 days.

[0044] The experiment was divided into two parts:

[0045] 1. The mice were randomly divided into 4 groups for drug administration: control group, NJ241 group, MPTP group and NJ241+MPTP group. The day of drug administration was recorded as D1. The details are as follows:

[0046] Control group: Oral administration of normal saline every day for 28 consecutive days (D1-D28), and intraperitoneal injection of normal saline every day for the last 5 days (D24-D28);

[0047] NJ241 group: Oral administration of NJ241 for 28 consecutive days, and intraperitoneal injection of normal saline for the last 5 days;

[0048] MPTP group: Oral administration of normal saline every day for 28 consecutive days, and intraperitoneal injection of MPTP once a day for the last 5 days;

[0049] NJ241+MPTP group: NJ241 was orally administered every day for 28 consecutive days, and MPTP was intraperitoneally injected once a day for the last 5 days.

[0050] MPTP was dissolved in saline at a dosage of 30 mg / kg (mouse weight 20 g, dosage volume 0.2 mL), and NJ241 was diluted with saline at a dosage of 1 × 10 9 CFU (dosing volume 0.2 mL).

[0051] The mice were subjected to behavioral tests after 28 days and euthanized on day 29 (D29).

[0052] The experimental process is as follows Figure 1 As shown in a in .

[0053] In the above experiments, behavioral tests include:

[0054] (1) Independent movement and standing

[0055] The mice were placed in a locomotor activity device, and the number of locomotor activities and standing times of the mice were measured in a quiet and dark environment within 5 minutes.

[0056] (2) Rotarod test

[0057] Before the experiment, two 30 rpm rotarod training sessions were performed for 120 s. On the day of the experiment, the parameters of the mouse rotarod fatigue instrument were set to 30 rpm, and the mice were placed in the rotarod fatigue instrument. The time when the mouse fell for the first time within 5 minutes was recorded, i.e., the latency period of the mouse falling.

[0058] (3) Suspension test

[0059] In order to test the motor coordination of mice, a hanging test was performed. According to the existing experimental method (Hu F, Duan M, Peng N. Knockdown of TRB3 improved the MPP(+) / MPTP-induced Parkinson's disease through the MAPK and AKT signaling pathways. Neurosci Lett. 2019.709: 134352.), a horizontal hanging line with a thickness of about 2 mm and a length of 50-60 cm was used to test the hanging ability of mice. Each mouse started by hanging on the wire with its two front paws. If the mouse could grab the wire with its two hind paws at the same time, it would get 3 points; if the mouse only grabbed the wire with one hind paw and two front paws, it would get 2 points; if the mouse could only grab the wire with its two front paws, it would get 1 point; if the mouse fell, it would get 0 points.

[0060] (4) Body weight and gastrointestinal motility test

[0061] 20 minutes before sampling, 0.2 mL of 0.5% Evans blue solution was intragastrically administered. 20 minutes after instillation, the farthest distance of Evans blue solution transported from the pylorus in the small intestine was measured.

[0062] (5) Immunofluorescence

[0063] Brain and colon tissues were fixed with 4% paraformaldehyde for 6 hours. Then, they were dehydrated in 25% sucrose solution until the tissue sank to the bottom. The thickness of the brain tissue including the substantia nigra was 30 μm. The colon tissue was sliced ​​10 μm thick. The slices were washed 3 times with 0.01 M PBS for 5 minutes each time, then treated with permeabilization solution for 15 minutes and washed again. The slices were incubated with rabbit anti-TH polyclonal antibody (1:2000), rabbit anti-GFAP polyclonal antibody (1:8000), rabbit anti-Iba-1 monoclonal antibody (1:4000), rabbit anti-GLP-1R polyclonal antibody (1:200), rabbit anti-ZO-1 polyclonal antibody (1:1000), and rabbit anti-Occludin polyclonal antibody (1:200) at room temperature for 20 hours. After incubation, the slices were washed 3 times for 5 minutes each time, and then incubated with Alexa Fluor 594-labeled goat anti-rabbit IgG antibody (1:400) for 2 hours in the dark. After incubation, the sections were washed three times with PBS for 5 minutes each time. Finally, the sections were dried and sealed with fluorescent sealing medium, and the images were taken with an Olympus BX51 fluorescence microscope (GFAP images should be taken at the same exposure).

[0064] (6) Immunoblotting

[0065] Unfixed brain tissue and colon tissue were quickly frozen with liquid nitrogen and stored at -80°C. Protein was extracted from the tissue, and 100 μL tissue lysis buffer (Cat. No. R0010, Solarbio, Beijing), 1 μL PMSF (phenylmethylsulfonyl fluoride, Cat. No. P0100, Solarbio, Beijing) and 1 μL phosphatase inhibitor (Cat. No. P1260, Solarbio, Beijing) were added to each 10 mg tissue. Ultrasonication was performed at 4°C and 12000 rpm in an ultracentrifuge for 15 min, and the supernatant was collected. The protein concentration was determined by BCA protein concentration assay (PC0020, Solarbio, Beijing), and 10 μL of protein solution containing 20 μg of protein was finally obtained.

[0066] After protein quantification, prepare 4% concentrating gel and 10% or 12% separation gel according to the protein molecular weight. After electrophoresis of 10 μL protein per lane, transfer the protein to a PVDF membrane and block with 5% skim milk for 3 hours. Incubate with rabbit anti-polyclonal antibody (1:2000), rabbit anti-GFAP polyclonal antibody (1:5000), rabbit anti-ZO-1 polyclonal antibody (1:1000), rabbit anti-human tight junction protein polyclonal antibody (1:1000), or mouse anti-GAPDH polyclonal antibody (1:5000) at 4°C overnight. The next day, wash the PVDF membrane three times with TBST for 5 minutes each time. After washing with TBST, add HRP-labeled anti-mouse or anti-rabbit IgG (1:50000) and incubate on a shaker at room temperature for 2 hours. Finally, use Chemi-Doc TM Touch (Bio-Rad) for chemiluminescence and visualization of protein bands. Finally, Image J software was used to quantify protein bands, with GAPDH as an internal reference. The experiment was repeated three times for each target protein in each mouse.

[0067] (7) Gut microbiome analysis

[0068] Mouse feces were collected, immediately frozen in liquid nitrogen, and stored at -80°C for further testing. Total DNA was extracted and purified from feces using the Spin Kit for Soil (Omega Bio-tek, Norcross, GA, USA). The V3-V4 region of bacterial 16S rRNA was amplified using the 338F primer 5'-ACTCCTACGGGAGGCAGCAG-3' and the 806R primer 5'-GGACTACHVGGGTWTCTAAT-3'. The amplified products were sequenced on the Illumina MiSeq PE300 platform (Meiji Bio), and OTU clustering was performed based on 97% similarity using UPARSE software (http: / / drive5.com / uparse / , version 7.1), and chimeras were removed. Species classification annotation was performed using the RDP classifier (http: / / rdp.cme.msu.edu / , version 2.2) and compared with the Silva 16S rRNA database (v138). The Chao1 index and Simpson index were used for alpha diversity analysis, and the weighted UniFrac phylogenetic distance matrix was used for principal component analysis (PCoA). The relative abundance at the phylum level was used to determine the bacterial community structure, and heat maps were used to compare the differences at the genus level among taxa.

[0069] (8) Statistical analysis

[0070] The number of TH-positive and Iba-1-positive cells on both sides of the SN on the slices was detected, and GFAP was detected using Image Pro Plus to measure the average optical density. All statistical analyses were performed using SPSS21.0, and the experimental results were analyzed using one-way analysis of variance. All parameters were compared multiple times, and the data were expressed as mean ± standard deviation (SEM). P < 0.05 was considered statistically significant.

[0071] result:

[0072] (1) NJ241 can improve MPTP-induced weight loss, gastrointestinal dysmotility and behavioral disorders in mice:

[0073] The experimental process is as follows Figure 1 As shown in a. During the experiment, mice were weighed at fixed times. The results showed that the body weight of mice in the control group and NJ241 group remained stable during the experiment. However, the body weight of mice in the MPTP group and NJ241+MPTP group began to decrease after the injection of MPTP until the end of the experiment (P=0.031, P=0.034).

[0074] The behavioral results of the behavioral test before the experiment showed that there were no statistical differences in the number of motor activities, number of independence, latency of rotation and hanging scores among the groups. The behavioral results after injection of MPTP showed that there were no statistical differences in the number of spontaneous activities, number of independence, rotarod test (latency) and hanging test scores between the NJ241 group and the control group. Compared with the control group and the NJ241 group, the number of spontaneous activities, number of independence, rotarod test (latency) and hanging test scores of the mice in the MPTP group were significantly decreased (compared with the control group, the number of spontaneous activities P<0.001, the number of independence P<0.001, the latency P=0.04, and the hanging test P=0.001; compared with the NJ241 group, the number of spontaneous activities P<0.001, the number of independence P<0.001, the latency P=0.005, and the hanging test P=0.003). The number of spontaneous activities, independence times, and hanging test scores in the NJ241 intervention group were significantly increased (P=0.001, P=0.045, P=0.028), but there was no significant difference in latency between the NJ241 group and the MPTP group (P>0.05).

[0075] To detect the gastrointestinal motility of mice, Evans blue solution was administered orally, and the transport distance of Evans blue in the small intestine was measured at 20 minutes. The results showed that compared with the control group, the intestinal transport distance of the MPTP group mice was significantly reduced ( Figure 1 Compared with the MPTP group, the intestinal transit distance of mice in the NJ241+MPTP group was significantly increased ( Figure 1C in (P=0.024).

[0076] (2) NJ241 alleviates MPTP-induced dopaminergic neuron damage:

[0077] TH is the rate-limiting enzyme in the synthesis of dopamine, and its expression level can reflect the survival of dopaminergic neurons. Immunofluorescence and Western Blot were used to detect the effect of NJ241 on TH expression in SN. The results showed that there was no statistical difference in the number of TH-positive cells between the NJ241 group and the control group. The number of TH-positive cells in the MPTP group was significantly lower than that in the control group. Compared with the MPTP group, the number of TH-positive cells increased significantly ( Figure 2 D in (P<0.001). WB test results are shown in Figure 2 As shown in F. There was no significant difference in TH protein expression between the NJ241 group and the control group. Compared with the control group, the TH protein expression level in the MPTP group was significantly decreased ( Figure 2 F in the , P = 0.037), compared with the NJ241 group, the TH protein expression level was significantly decreased ( Figure 2 F, P = 0.006). The expression level of TH protein in the NJ241+MPTP group was significantly higher than that in the MPTP group ( Figure 2 F in (P=0.031).

[0078] (3) NJ241 inhibits MPTP-induced glial cell activation:

[0079] The expression levels of astrocytes and microglia are important indicators for determining the degree of neuroinflammation. To investigate the effect of NJ241 intervention on inflammation in the substantia nigra of mice, we detected the average optical density of the astrocyte marker GFAP and the level of the microglia marker Iba-1 by immunofluorescence and immunoblot analysis.

[0080] The experimental results showed that there was no significant difference in the number of Iba-1 positive cells and the average optical density of GFAP between the NJ241 group and the control group. The number of Iba-1 positive cells and the average optical density of GFAP in the substantia nigra in the MPTP group were significantly higher than those in the control group and the NJ241 group (Iba-1: P<0.001, P<0.001; GFAP: P<0.001, P<0.001). The average optical density of GFAP and the expression level of Iba-1 in the NJ241+MPTP group were significantly lower than those in the MPTP group (P<0.001, P<0.001). The results of immunoblotting, such as Figure 3As shown in Figure E, there was no significant difference in GFAP protein level between the NJ241 group and the control group, while the GFAP protein level in the MPTP group was significantly higher than that in the control group and the NJ241 group (P=0.013, P=0.042). The GFAP protein level in the NJ241+MPTP group was significantly lower than that in the MPTP group (P=0.045).

[0081] The continuous activation of astrocytes and microglia releases a variety of inflammatory mediators and cytokines, such as interleukin-1β (IL-1β) and interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). The release of these inflammatory mediators and cytokines can lead to inflammatory damage and neuronal death. The expression levels of IL-1β, IL-6, and NF-κB in SN were detected, and the results showed that there was no statistically significant difference in IL-1β expression between the NJ241 group and the control group (P=0.439). Compared with the control group and the NJ241 group, the expression of IL-1β in the MPTP group was significantly increased (P=0.001, P=0.003). The IL-1β in the NJ241+MPTP group was significantly lower than that in the MPTP group (P=0.049). The expression level of IL-6 in the MPTP group was significantly higher than that in the NJ241 group (P=0.014), and there was no statistically significant difference between the other three groups. The results showed that the expression level of NF-κB in the MPTP group was significantly higher than that in the control group and NJ241 group (P=0.001, P<0.001), and the expression level of NF-κB protein was significantly reduced in the NJ241+MPTP group (P=0.005).

[0082] (4) NJ241 can improve the destruction of the substantia nigra blood-brain barrier induced by MPTP:

[0083] The destruction of tight junction proteins in the substantia nigra leads to a decrease in the permeability of the blood-brain barrier, resulting in the occurrence of neuroinflammation and the death of dopaminergic neurons. To evaluate the protective effect of NJ241 on the blood-brain barrier, the expression levels of ZO-1 and tight junction proteins in the SN were detected by WB. The results showed that there was no statistically significant difference in the expression of ZO-1 between the NJ241 group and the control group. Compared with the control group, the level of ZO-1 in the MPTP group was significantly reduced (P=0.008), while that in the NJ241 group was significantly reduced (P=0.026). The level of ZO-1 in the NJ241+MPTP group was significantly increased compared with the MPTP group (P=0.006). There was no statistically significant difference in the expression of tight junction proteins between the NJ241 group and the control group. Compared with the control group and the NJ241 group, the level of tight junction proteins in the MPTP group was significantly reduced (P<0.001, P=0.005), and that in the NJ241+MPTP group was significantly increased compared with the MPTP group (P=0.003).

[0084] (5) NJ241 reverses MPTP-induced intestinal flora disturbance in mice

[0085] To test whether MPTP can change the intestinal flora and whether NJ241 can improve the dysbiosis caused by MPTP, 16S rRNA gene sequencing was performed on the fecal samples of each group of mice. The Chao1 index results showed that there was no statistically significant difference among the MPTP group, the control group, and the NJ241 group ( Figure 5 A in the figure). The Chao1 index of the NJ241+MPTP group was significantly higher than that of the control group and the NJ241 group (P=0.028, P=0.018), but there was no significant difference compared with the MPTP group. The Simpson index of the MPTP group was significantly lower than that of the control group (P=0.013), and the Simpson index of the NJ241+MPTP group was significantly lower than that of the control group (P=0.018), but there was no significant difference compared with the MPTP group. β diversity can distinguish the spatial distribution patterns of different groups. The closer the attributes of two objects are, the higher their similarity is, and the closer the distance between them is. The diversity results showed that there was no statistically significant difference between the NJ241 group and the control group, while the difference between the MPTP group and the control group was large. The NJ241+MPTP group was also different from the MPTP group ( Figure 5 C).

[0086] By further analyzing the community composition, such as Figure 5 As shown in D. At the phylum level, the relative expression abundance of Firmicutes was significantly decreased after MPTP treatment compared with the control group and NJ241 group (P = 0.021, P = 0.034); after MPTP treatment, the relative expression abundance of Bacteroidota was significantly increased compared with the control group and NJ241 group (P = 0.003, P = 0.002). However, compared with the MPTP group, the relative expression abundance of Bacteroidetes in the NJ241 + MPTP group showed a significant downward trend, and the expression levels of the NJ241 group and the NJ241 + MPTP group also showed a significant upward trend.

[0087] Compared with the control group, the relative abundance of the beneficial bacteria lactobacillus in the other three groups was significantly reduced (P = 0.02, P = 0.037, P = 0.012). The relative abundance of the pro-inflammatory bacteria norank_f_Muribaculaceae was significantly higher than that of the control group and NJ241 group after MPTP treatment (P = 0.008, P = 0.005), and there was a downward trend in the NJ241 + MPTP group compared with the MPTP group, but there was no statistical difference. In the NJ241 and NJ241 + MPTP groups, the relative abundance of Dubosiella showed a significant upward trend. The relative abundance of the pro-inflammatory bacteria Bacteroides and Prevotellaceae-UCG-001 showed an increasing trend in the MPTP group compared with the control group and NJ241 group, and a decreasing trend in the NJ241 + MPTP group compared with the MPTP group.

[0088] The heat map method was used to analyze the changes in microbial flora at the genus level. Figure 5As shown in F. Coriobacteriaceae_UCG-002, Candidatus-Stoquefichus, Ileibacterium, Parvibacter, Turicibacter, and Lachnoclostridium in the NJ241 group were significantly lower than those in the control group. In contrast, the relative expression abundances of Akkermansia, Rikenella, Roseburia, Roseburia, and Faecalibaculum in the NJ241 group were significantly higher than those in the control group. The relative expression abundances of Rikenellaceae_RC9_gu_group, Turicibacter, norank_f_Oscillospiraceae, Parabacteroides, Erysipelatoclostridium, Odoribacte, Bacteroides, Prevotellaceae_UCG-001, Alistipes, and unclassified_f_Prevotellaceae were higher in the MPTP group compared with the control group. The relative expression abundances of Coriobacteriaceae_UCG-002, Candidatus-Stoquefichus, Parvibacter, Candidatus_Arthrornitus, and Roseburia in the MPTP group were lower than those in the control group. Compared with the MPTP group, the relative expression abundances of norank_f_Oscillospiraceae, Turicibacter, Parabacteroides, Erysipelatoclostridium, and Odoribacte were lower in the NJ241+MPTP group, while the relative expression abundances of Akkermansia, Anaerostipes, Eubacterium_fissicatena_group, and Eubacterium_xylanophilum_group were higher.

[0089] (6) NJ241 promotes colonic GLP-1 secretion and substantia nigra GLP-1R / PGC-1α expression

[0090] Parkinson's disease and diabetes are both age-related chronic diseases, and there is increasing evidence that the two are related. Search the keywords "Parkinson's disease" and "diabetes" on DisGeNET, and download all genes related to Parkinson's disease and diabetes published on the website. Enter the 43 genes commonly associated with Parkinson's disease and diabetes into the STRING website to construct a protein-protein interaction network. Then, use CytoScape to analyze the PPI network results and find that GLP-1R is related to the PPARGC1A (PGC-1α) gene.

[0091] GLP-1 is an incretin hormone produced by distal intestinal endocrine L cells in response to food intake. It can cross the blood-brain barrier and bind to GLP-1R in the central nervous system to exert various physiological effects. In order to detect the expression levels of GLP-1 and GLP-1R in SN in the colon, the present invention detected their expression by immunofluorescence and WB. Figure 6 As shown in Figure B, the expression level of colonic GLP-1 protein was significantly lower in the MPTP group than in the control group (P = 0.011); it was significantly higher in the NJ241 + MPTP group than in the MPTP group (P = 0.018), but there was no statistical difference compared with the control group. The serum GLP-1 concentration was detected by ELISA ( Figure 6 D), there was no significant difference between the control group and the NJ241 group. The serum GLP-1 concentration in the MPTP group was significantly lower than that in the control group and the NJ241 group (P<0.001, P<0.001). The serum GLP-1 concentration in the NJ241+MPTP group was significantly higher than that in the MPTP group (P=0.001).

[0092] WB results showed that there was no significant difference in the expression level of GLP-1R protein in SN between the NJ241 group and the control group ( Figure 6 E and F in the figure). Compared with the control group and NJ241 group, the GLP-1R protein expression level in the MPTP group was significantly decreased (P=0.002, P=0.001), while the GLP-1R protein expression level in the NJ241+MPTP group was significantly increased compared with the MPTP group (P=0.044). Immunofluorescence was used to detect GLP-1R-positive cells in SN cells. There was no statistically significant difference in GLP-1R-positive cells between the NJ241 group and the control group. Compared with the control group and NJ241 group, the number of GLP-1R-positive cells in the MPTP group was significantly decreased (P<0.001, P<0.001), while the number of GLP-1R-positive cells in the NJ241+MPTP group was significantly increased compared with the MPTP group (P<0.001, Figure 6 Middle G).

[0093] (7)Preliminary experiments have found that GLP-1R agonists can reduce inflammatory responses in SN through the GLP-1R-AMPK-PGC-1α-NF-κB signaling pathway. The expression level of PGC-1α in SN was detected by WB. The results showed that there was no significant difference in the expression level of PGC-1α between the NJ241 group and the control group. Compared with the control group and the NJ241 group, the expression level of PGC-1α in the MPTP group was significantly decreased (P=0.015, P=0.012), and the expression level of PGC-1α in the NJ241+MPTP group was significantly increased compared with the MPTP group (P=0.018).

[0094] Using animal behavior, immunofluorescence, and immunoblotting to detect the expression of TH, GFAP, and Iba1 in the substantia nigra, and to measure changes in the substantia nigra blood-brain barrier, it was found that NJ241 can improve movement disorders in PD mice, increase the number and protein levels of dopaminergic neurons; inhibit the activation of substantia nigra glial cells, and improve the blood-brain barrier. NJ241 improved the intestinal dysbiosis caused by MPTP, reduced the abundance of inflammatory bacteria, and increased the abundance of beneficial bacteria. NJ241 also increased the expression level of GLP-1 in the colon and promoted the expression of GLP-1R / PGC-1α in the substantia nigra. The results showed that NJ241 promoted the expression of GLP-1 in the colon, and GLP-1 acted on the GLP-1R in the substantia nigra to activate PGC-1α, thereby exerting a neuroprotective effect on PD mice.

[0095] The experimental results showed that the MPTP group reduced the expression level of colonic GLP-1, NJ241 increased the expression level of colonic GLP-1, MPTP reduced the expression of GLP-1R and PGC-1α in the substantia nigra, and NJ241 reversed the reduction of GLP-1R and PGC-1α expression in the substantia nigra caused by MPTP. Therefore, animal lactic acid Bifidobacterium subspecies NJ241 promotes the expression of colonic GLP-1, GLP-1 acts on GLP-1R in the substantia nigra, activates PGC-1α, and thus plays a neuroprotective role in PD mice ( Figure 7 ).

Claims

1. Use of Bifidobacterium animalis subsp. Lactis in the preparation of neuroprotective drugs, characterized in that: The preservation number of the animal Bifidobacterium lactis subspecies is CGMCC No.20816; the neuroprotection includes: protecting dopaminergic neurons, alleviating neuroinflammation, and activating PGC-1α.

2. The use according to claim 1, characterized in that: The reduction of neuroinflammation includes: improving the blood-brain barrier and inhibiting the activation of substantia nigra glial cells.

3. The use according to claim 2, characterized in that: The inhibition of nigral glial cell activation includes reducing the expression levels of inflammatory mediators and cytokines in nigral glial cells.

4. The use according to claim 3, characterized in that: The substantia nigra cells include astrocytes or microglia.

5. The use according to claim 4, characterized in that: The protection of dopaminergic neurons includes increasing the number and protein level of dopaminergic neurons.

6. The use according to claim 5, characterized in that: The activation of PGC-1α includes promoting the expression of colon GLP-1 and acting on GLP-1R in the substantia nigra to activate PGC-1α.

7. The use of Bifidobacterium animalis subsp. lactis in the preparation of a medicament for preventing or treating a neurodegenerative disease is characterized in that: The preservation number of the animal Bifidobacterium lactis subspecies is CGMCC No.20816.

8. The use according to claim 7, characterized in that: The neurodegenerative diseases include Parkinson's disease.